Phase Ib trial of bryostatin 1 in patients with refractory malignancies.

A Phase Ib trial of bryostatin 1, a macrocyclic lactone and protein kinase C (PKC) activator, was conducted in patients with refractory nonhematological malignancies with the primary goal of determining whether down-regulation of peripheral blood mononuclear cell (PBMNC) PKC activity could be achieved in vivo in humans. Patients (four patients/cohort) received bryostatin 1 (25 microg/m2) as a 1-h infusion weekly three times every 4 weeks, but to study the schedule dependence of pharmacokinetics and pharmacodynamics, the first dose was administered according to one of three schedules: (a) a 1-h infusion; (b) a 24-h infusion; or (c) a split course (12.5 microg/m2 as a 30-min infusion) on days 1 and 4. Conventional toxicities (grades I-III) included myalgias, fever, anemia, fatigue, phlebitis, and headache; in addition, two patients in cohort 3 experienced transient elevations in liver function tests, although these patients had preexisting liver metastases. No objective clinical responses were encountered. Effects on PBMNC PKC activity were heterogeneous. Several patients in cohorts 1 and 2 experienced significant declines in activity (approximately 50%) that were sustained in some cases for periods of > or = 72 h. Comparison of 72-h with baseline values for all three patient cohorts combined revealed a trend toward PKC down-regulation (P = 0.06; signed rank test). For each schedule, plasma bryostatin 1 levels were below the level of detection of a platelet aggregation-based bioassay (3-4 nm). Bryostatin 1 administration failed to produce consistent alterations in lymphocyte immunophenotypic profiles, interleukin 2-induced proliferation, or cytotoxicity, although two of three samples from patients in cohort 3 did show significant posttreatment increases in proliferation. Moreover, in some patients, bryostatin 1 treatment increased lymphokine-activated killer cell activity. These findings indicate that bryostatin 1 doses of 25 microg/m2 can induce in vivo PBMNC PKC down-regulation in at least a subset of patients and raise the possibility that higher bryostatin 1 doses may be more effective in achieving this effect.

[1]  Y. Hannun.  Functions of Ceramide in Coordinating Cellular Responses to Stress , 1996, Science.

[2]  S. Grant,et al.  Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  S. Grant,et al.  Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis. , 1996, Experimental cell research.

[4]  G. Pettit,et al.  Ubiquitination of Protein Kinase C-α and Degradation by the Proteasome* , 1996, The Journal of Biological Chemistry.

[5]  Z. Szallasi,et al.  The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. , 1996, Cancer research.

[6]  A. Kraft,et al.  Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. , 1996, Cancer research.

[7]  G. Jayson,et al.  A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. , 1995, British Journal of Cancer.

[8]  S. Grant,et al.  A sensitive platelet activation-based functional assay for the antileukemic agent bryostatin 1. , 1995, Anti-cancer drugs.

[9]  K. Kohn,et al.  Induction of a common pathway of apoptosis by staurosporine. , 1994, Experimental cell research.

[10]  S. Grant,et al.  Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. , 1994, Biochemical pharmacology.

[11]  Z. Szallasi,et al.  Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. , 1994, The Journal of biological chemistry.

[12]  A. Harris,et al.  Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In Vivo , 1993 .

[13]  P. Stern,et al.  A phase I study of intravenous bryostatin 1 in patients with advanced cancer. , 1993, British Journal of Cancer.

[14]  A. Kraft,et al.  In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. , 1993, Cancer research.

[15]  M. Melamed,et al.  Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. , 1993, Leukemia.

[16]  T. Mustelin,et al.  Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C. , 1993, Journal of immunology.

[17]  P. Lin,et al.  Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA. , 1992, Cancer research.

[18]  G. Guy,et al.  Two protein kinase C activators, bryostatin-1 and phorbol-12-myristate-13-acetate, have different effects on haemopoietic cell proliferation and differentiation. , 1992, Cellular signalling.

[19]  N. Davidson,et al.  Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. , 1992, Cancer research.

[20]  K. Heeg,et al.  Triggering of CD8+ cytotoxic T lymphocytes via CD3-epsilon differs from triggering via alpha/beta T cell receptor. CD3-epsilon-induced cytotoxicity occurs in the absence of protein kinase C and does not result in exocytosis of serine esterases. , 1991, Journal of immunology.

[21]  J. Lotem,et al.  Rescue from programmed cell death in leukemic and normal myeloid cells. , 1991, Blood.

[22]  L. Schuchter,et al.  Successful treatment of murine melanoma with bryostatin 1. , 1991, Cancer research.

[23]  B. A. Hocevar,et al.  Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells. , 1991, The Journal of biological chemistry.

[24]  G. Demetri,et al.  The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. , 1990, Blood.

[25]  W. May,et al.  Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. , 1990, Blood.

[26]  S. Kaufmann.  Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. , 1989, Cancer research.

[27]  S. Orrenius,et al.  Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. , 1989, The Journal of biological chemistry.

[28]  A. Gescher,et al.  Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells , 1989, International journal of cancer.

[29]  W. May,et al.  Activation of human T lymphocytes by bryostatin. , 1988, Journal of immunology.

[30]  H. Bear,et al.  Phenotype of syngeneic tumor-specific cytotoxic T-lymphocytes and requirements for their in vitro generation from tumor-bearing host and immune spleens. , 1988, Cancer research.

[31]  A. Kraft,et al.  Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Yuspa,et al.  Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. , 1987, Carcinogenesis.

[33]  A. Kraft,et al.  Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[34]  E. Rozengurt,et al.  Disappearance of Ca2+-sensitive, phospholipid-dependent protein kinase activity in phorbol ester-treated 3T3 cells. , 1984, Biochemical and biophysical research communications.

[35]  J. Clardy,et al.  Isolation and structure of bryostatin 1 , 1982 .

[36]  R. Mohammad,et al.  Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents. , 1994, Cancer research.

[37]  S. Grant,et al.  Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C. , 1994, Oncology research.

[38]  D. Longo,et al.  Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. , 1992, Cancer research.

[39]  D. Conrad.  FcεRII/CD23: The Low Affinity Receptor for IgE , 1990 .

[40]  A. Bøyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. , 1968 .